Full Press Release Details
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First in Class Pol Theta Helicase Inhibitor Development Candidate.
IDYA
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First in Class Pol Theta Helicase Inhibitor Development Candidate
Key Takeaway: IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First in Class Pol Theta Helicase Inhibitor Development Candidate
Price reaction · baseline $9.61 (2022-08-26 close) · 1 other IDYA headline(s) in the window, move may be shared
day 0 close
-0.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma